Previous 10 | Next 10 |
The following slide deck was published by KalVista Pharmaceuticals, Inc. in conjunction with this Read more ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Cantor Global Healthcare Conference on Thursday, October 3, 20...
KalVista Pharmaceuticals ( KALV ) is a small-cap pharmaceutical company seeking to develop and commercialize small molecule protease inhibitors to treat diseases with significant unmet need. The company's initial focus is on Hereditary Angioedema ((HAE)) and Diabetic Macular Edema ((DME)). The...
Your fear is 100% dependent on you for its survival .” - Steve Maraboli Today, we look at a small developmental concern that has not has a lot of news flow in recent months and whose stock is down some 40% from recent highs. However, several key readouts through year end could ch...
Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio ...
KalVista Pharmaceuticals (NASDAQ: KALV ) initiated with Outperform rating and $31 (83% upside) price target at SVB Leerink. More news on: KalVista Pharmaceuticals, Inc., Gilead Sciences, Inc., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...
Introduction KalVista ( KALV ) revealed their fiscal year financial results this morning. Here are some key points: Phase 2 KVD900 HAE data due before end of year. After BioCryst ( BCRX ) revealed underwhelming HAE data, KalVista will have a chance to differentiate themselves. Th...
KalVista Pharmaceticals (NASDAQ: KALV ): Q4 GAAP EPS of -$0.49 beats by $0.30 . Revenue of $2.93M (-39.5% Y/Y) misses by $1.11M . Press Release More news on: KalVista Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
– Martin Edwards, MD, Elected as Chair – – Chair Richard H. Aldrich Resigns in Planned Transition – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializatio...
– Martin Edwards, MD, Elected as Chair – – Chair Richard H. Aldrich Resigns in Planned Transition – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializatio...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...